- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07716020
XPAD European Feasibility Study
Prospective, Non-randomized, European Feasibility Clinical Study to Assess the Safety and Performance of the Xeltis Peripheral Artery Disease (XPAD) Bypass Conduit.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Sandra Kohler
- Número de teléfono: +31 (0) 6 55 55 57 14
- Correo electrónico: sandra.kohler@xeltis.com
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Participants with peripheral artery occlusion who require elective lower-limb bypass surgery
- Participant has Rutherford grade 3 or 4 occlusive vascular disease and TASC C or D lesions.
- At least 18 years of age at screening
- Suitable anatomy while avoiding joints (assessed by a pre-procedural contrasted CT scan or previous angiogram assessed up to 90 days prior to baseline)
- Participant has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent
- Participant has been informed and agrees to pre- and post-procedure follow-up, including follow-up angiography
- Life expectancy of at least 24 months
Exclusion Criteria:
- Participant requires, or is scheduled for, a cardiac surgical procedure or a different vascular surgical procedure within 30 days of study procedure.
- Stroke or myocardial infarction event within 6 weeks of the procedure or evidence of prior massive stroke (Modified Rankin Scale 3 or above)
- History of acute arterial occlusion requiring an emergent intervention within the last 12 months
- Severe chronic renal insufficiency (serum creatinine >2.5 mg/dL) or undergoing hemodialysis
- Previous renal transplant
- Uncontrolled arterial hypertension (BP >200 mmHg) at 2 successive readings
- Uncontrolled or poorly controlled diabetes
- Abnormal blood values that could influence participant recovery and or/ graft hemostasis
- Reduced liver function, defined as: >2x the upper limit of normal for serum bilirubin, International Normalized Ratio (INR) >1.5 or prothrombin time (PT) >18 seconds
- Any active local or systemic infection
- Known heparin- induced thrombocytopenia, active bleeding disorder and/or any coagulopathy or thromboembolic disease
- Allergies to study device (nitinol) or agents/medication, such as contrast agents, aspirin or NOACs, that can't be controlled medically
- Previous enrolment in this study
- Participant is participating in another study
- Pregnant or breastfeeding woman or woman in fertile period not taking adequate contraceptives
- Any other condition which, in the judgement of the investigator would preclude adequate evaluation for the safety and performance of the study conduit
Intra-operative exclusion criteria:
1. Unsuitable anatomy to implant the XPAD conduit (e.g. target vessel diameter smaller than anticipated; severe calcification)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: XPAD
|
The XPAD bypass conduit is a sterile, restorative biodegradable polymer-based vascular conduit, consisting of a tubular structure with a 33cm length and 6mm inner diameter.
It is comprised of a highly porous polymer matrix and an embedded electropolished nitinol reinforcement layer (Strain Relief System).
The XPAD conduit is in a straight configuration and may be implanted in the lower limb for elective bypass surgery.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Primary patency rate
Periodo de tiempo: 12 months post-implant
|
Primary patency defined as the interval between conduit implantation and the first intervention to maintain or restore patency
|
12 months post-implant
|
|
Freedom from device-related SAE
Periodo de tiempo: Day 1, 30 days, 6 months, and 12 months post-implant
|
Day 1, 30 days, 6 months, and 12 months post-implant
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Implantation success rate
Periodo de tiempo: Day 1
|
Implantation success defined as a technically successful XPAD conduit implantation in the planned configuration, free from kinking and tension in the anastomoses, and a patent XPAD conduit at the moment of discharge.
|
Day 1
|
|
Freedom from Major Bleeding events
Periodo de tiempo: Day 1, 30 days and 6 months post-implant
|
Major Bleeding defined as type 3, 4 or 5 bleeding according to the Bleeding Academic Research Consortium (BARC) classifications
|
Day 1, 30 days and 6 months post-implant
|
|
Patency (primary, primary assisted, and secondary) rates
Periodo de tiempo: 6, 12, 24, 36, 48 and 60 months post-implant
|
Primary patency defined as the interval between conduit implantation and the first intervention to maintain or restore patency. Assisted primary patency defined as the interval between conduit implantation and the first occlusion (thrombosis), including interventions (operative or endovascular) aimed to maintain the functionality the conduit. Secondary patency defined as the interval between conduit implantation and abandonment with or without interventions (operative or endovascular) aimed to maintain the functionality the conduit, including occurrence of a censored event (death, change of modality, loss of follow-up). |
6, 12, 24, 36, 48 and 60 months post-implant
|
|
Freedom from device-related SAE
Periodo de tiempo: 24, 36, 48 and 60 months post-implant
|
24, 36, 48 and 60 months post-implant
|
|
|
Rate of wound/conduit infections
Periodo de tiempo: 30 days, 6, 12, 24, 36, 48 and 60 months post-implant
|
30 days, 6, 12, 24, 36, 48 and 60 months post-implant
|
|
|
Freedom from Major Amputations
Periodo de tiempo: 30 days, 6, 12, 24, 36, 48, and 60 months post-implant
|
Major Amputation defined as any amputation that results in limb shortening
|
30 days, 6, 12, 24, 36, 48, and 60 months post-implant
|
|
Freedom from all-cause mortality
Periodo de tiempo: 30 days, 6, 12, 24, 36, 48, and 60 months post-implant
|
30 days, 6, 12, 24, 36, 48, and 60 months post-implant
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- XEL-CR-17
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .